Autonomic/CV Drugs Practice Questions

Q: Which antithyroid drug is safer during the first trimester of pregnancy?

Propylthiouracil. ***Propylthiouracil*** - **Propylthiouracil (PTU)** is the preferred drug for treating hyperthyroidism in the **first trimester of pregnancy** due to a lower risk of teratogenic effects compared to methimazole or carbimazole. - While PTU carries a risk of hepatic toxicity, it is generally favored during early pregnancy to avoid the established teratogenic risks of other thionamides. *Radioactive iodine* - **Radioactive iodine (RAI)** is absolutely contraindicated in pregnancy as it crosses the placenta and can cause permanent **fetal hypothyroidism** or **agenesis of the fetal thyroid gland**. - Its use can lead to the destruction of the fetal thyroid, which is unacceptable given the availability of safer alternatives. *Carbimazole* - **Carbimazole** is converted to methimazole in the body and is associated with a higher risk of **fetal embryopathy** during the first trimester, including aplasia cutis, choanal atresia, and esophageal atresia. - It should generally be avoided in the first trimester if possible, switching to PTU instead. *Methimazole* - **Methimazole** is structurally similar to carbimazole and also carries a significant risk of **teratogenic effects** such as **aplasia cutis**, omphalocele, and choanal atresia when used in the first trimester. - It is often reserved for the second and third trimesters if a thionamide is required, or for patients who cannot tolerate PTU, but ideally avoided in early pregnancy. *Propranolol* - **Propranolol** is a beta-blocker used for symptomatic management of hyperthyroidism (controlling tachycardia, tremor, anxiety) but is not an antithyroid drug and does not treat the underlying hyperthyroidism. - While generally safe in pregnancy, it only provides adjunctive therapy and cannot replace definitive antithyroid treatment.

Q: A patient on SSRI sertraline was also prescribed amitriptyline and subsequently developed serotonin toxicity. What is the likely treatment for serotonin toxicity?

Cyproheptadine. ***Cyproheptadine*** - **Cyproheptadine** is a serotonin antagonist that can help reverse the effects of excessive serotonin in the central nervous system. - It works by blocking **serotonin 5-HT2A receptors**, which are implicated in the pathophysiology of serotonin toxicity. *Flumazenil* - **Flumazenil** is a benzodiazepine receptor antagonist used to reverse the effects of benzodiazepine overdose. - It has no role in the treatment of **serotonin toxicity**, as it does not affect serotonin pathways. *L-Carnitine* - **L-Carnitine** is a mitochondrial co-factor used in fatty acid metabolism, sometimes supplemented for certain metabolic disorders or muscle pain. - It does not have any direct action on **serotonin receptors** or the serotonin system, making it ineffective for serotonin toxicity. *Leucovorin* - **Leucovorin** (folinic acid) is used to counteract the effects of methotrexate toxicity or to enhance the effects of fluorouracil in chemotherapy. - It is not involved in modulating **neurotransmitter levels** or reversing the symptoms of serotonin toxicity. *Naloxone* - **Naloxone** is an opioid receptor antagonist used to reverse opioid overdose. - It has no effect on **serotonin receptors** or serotonergic pathways, making it ineffective for treating serotonin toxicity.

Q: Which of the following drugs is used in opioid maintenance therapy?

Buprenorphine. ***Buprenorphine*** - **Buprenorphine** is a **partial opioid agonist** used in opioid maintenance therapy to reduce cravings and withdrawal symptoms without producing the full euphoric effects of other opioids. - It is often combined with **naloxone** (as Suboxone) to prevent misuse by injection, as naloxone is only active if injected. - Buprenorphine has a **ceiling effect** for respiratory depression, making it safer than full agonists like methadone. *Naltrexone* - **Naltrexone** is an **opioid antagonist** that blocks opioid receptors, preventing the euphoric effects of opioids and reducing cravings. - While used in opioid use disorder treatment, it is primarily for relapse prevention and not typically for the active maintenance phase where agonist effects are desired. *Clonidine* - **Clonidine** is an **alpha-2 adrenergic agonist** primarily used to manage the **autonomic symptoms of opioid withdrawal**, such as anxiety, sweating, and rapid heart rate. - It does not directly act on opioid receptors and is not a primary agent for long-term opioid maintenance therapy. *Disulfiram* - **Disulfiram** is a drug used in the treatment of **alcohol use disorder**, not opioid use disorder. - It works by inhibiting acetaldehyde dehydrogenase, leading to an unpleasant reaction when alcohol is consumed. *Naloxone* - **Naloxone** is an **opioid antagonist** used for **emergency reversal of opioid overdose**, not for maintenance therapy. - It rapidly displaces opioids from receptors and reverses respiratory depression. - While combined with buprenorphine in Suboxone to prevent misuse, naloxone itself is not used for maintenance therapy.

Q: Which of the following growth hormone analogues is not used for the treatment of GH deficiency but is used in the treatment of HIV associated lipodystrophy?

Tesamorelin. ***Tesamorelin*** - **Tesamorelin** is a **growth hormone-releasing hormone (GHRH) analogue** approved specifically for the treatment of **HIV-associated lipodystrophy**. - It works by stimulating the natural production and release of endogenous growth hormone, which helps reduce **visceral adipose tissue** observed in this condition. - **Key distinction:** NOT used for GH deficiency, but specifically for lipodystrophy. *Sermorelin* - **Sermorelin** is also a **GHRH analogue**, but it is primarily used to diagnose and treat **growth hormone deficiency** in children. - It is not approved for lipodystrophy and works by stimulating the pituitary to secrete growth hormone. *Somatropin* - **Somatropin** is the recombinant form of **human growth hormone (GH)** itself, used to treat **growth hormone deficiency** in both children and adults. - While it can affect body composition, its primary indication is not HIV-associated lipodystrophy. *Mecasermin* - **Mecasermin** is recombinant **insulin-like growth factor-1 (IGF-1)** used to treat severe primary IGF-1 deficiency. - It is used for growth failure in children with GH gene deletion or GH receptor defects, not for HIV-associated lipodystrophy. *Pegvisomant* - **Pegvisomant** is a **growth hormone receptor antagonist** used to treat **acromegaly**, a condition caused by excessive growth hormone. - It works by blocking the action of growth hormone at its receptor, directly opposing the therapeutic goal for lipodystrophy.

Q: Caffeine is a widely used stimulant that promotes wakefulness. Which of the following mechanisms is responsible for this effect?

Adenosine antagonism. ***Adenosine antagonism*** - Caffeine acts as a **competitive antagonist** at **adenosine receptors** (primarily A1 and A2A) in the brain. - **Adenosine** is an inhibitory neurotransmitter that promotes drowsiness and reduces neuronal activity; by blocking its receptors, caffeine prevents this sedation and promotes wakefulness. - This is the **primary mechanism** responsible for caffeine's stimulant effects at typical dietary doses. *Increased discharge of norepinephrine from the locus ceruleus* - While increased **norepinephrine** can promote wakefulness, it is not the primary direct mechanism by which caffeine exerts its stimulant effects. - Caffeine may indirectly affect norepinephrine release as a downstream consequence of adenosine receptor blockade, but this is a secondary effect. *Release of histamine* - **Histamine** is indeed a neurotransmitter involved in wakefulness and arousal, but caffeine does not primarily promote wakefulness by directly causing histamine release. - Some antihistamines cause drowsiness by blocking central histamine receptors, but caffeine's mechanism is distinct from the histaminergic system. *Inhibition of phosphodiesterase* - Caffeine does inhibit **phosphodiesterase (PDE)** enzymes, leading to increased intracellular **cAMP** levels. - However, PDE inhibition occurs at significantly **higher concentrations** than those required for adenosine receptor antagonism, making it a less important mechanism for caffeine's typical stimulant effects at common dietary doses (1-3 cups of coffee). *Dopamine reuptake inhibition* - While some CNS stimulants (e.g., **methylphenidate**, **cocaine**) work primarily through dopamine reuptake inhibition, this is **not** caffeine's primary mechanism. - Caffeine may have minor indirect effects on dopamine neurotransmission through its adenosine receptor antagonism, but direct dopamine reuptake inhibition is not a significant mechanism of action.

Q: Which of the following is commonly used for maintenance therapy in opioid abuse?

Buprenorphine. ***Buprenorphine*** - **Buprenorphine** is a **partial opioid agonist** commonly used for the maintenance treatment of **opioid use disorder** due to its ability to reduce cravings and prevent withdrawal symptoms. - It has a "ceiling effect," meaning that its opioid effects level off at higher doses, which contributes to its **safety profile** and lower risk of overdose compared to full agonists. - Preferred over methadone in many settings due to its **superior safety profile**, lower abuse potential, and ability to be prescribed in office-based settings. *Clonidine* - **Clonidine** is an **alpha-2 adrenergic agonist** primarily used to manage **autonomic symptoms** of opioid withdrawal (e.g., sweating, hypertension), but it does not address cravings or provide opioid effects. - It is not considered a primary maintenance therapy for opioid use disorder. *Butorphanol* - **Butorphanol** is a **mixed opioid agonist-antagonist** often used for pain relief, but its partial agonist activity and potential for withdrawal in opioid-dependent individuals make it unsuitable for maintenance therapy in opioid abuse. - It can precipitate **opioid withdrawal** in patients who are opioid-dependent. *Naloxone* - **Naloxone** is an **opioid antagonist** used to rapidly reverse the effects of opioid overdose by blocking opioid receptors. - While critical in overdose situations, it is not used for maintenance therapy as it would induce immediate and severe opioid withdrawal symptoms. *Methadone* - **Methadone** is a **full opioid agonist** that is also used for maintenance therapy in opioid use disorder, particularly in specialized opioid treatment programs. - However, it requires **daily supervised dosing** in most jurisdictions, has a higher risk of overdose, respiratory depression, and QT prolongation, making buprenorphine often the **preferred first-line agent** for maintenance therapy.

Q: A patient presents with symptoms of tachycardia, tachypnea, hypertension, and hypocalcemia after consuming an unknown substance. The patient also has high anion gap metabolic acidosis. Which of the following substances was most likely consumed?

Ethylene glycol. ***Ethylene glycol*** - Ethylene glycol poisoning is characterized by **tachycardia**, **tachypnea**, **hypertension**, **hypocalcemia**, and a **high anion gap metabolic acidosis** due to the accumulation of toxic metabolites like oxalic and glycolic acids. - The formation of **calcium oxalate crystals** in the kidneys contributes to hypocalcemia and acute kidney injury, a hallmark of severe ethylene glycol toxicity. *Iron* - Iron overdose typically presents with **gastrointestinal symptoms** (vomiting, diarrhea, abdominal pain), shock, and metabolic acidosis, but not specifically with hypocalcemia or the characteristic crystal formation seen with ethylene glycol. - While it can cause metabolic acidosis, the absence of **hypocalcemia** and specific renal effects pointing to oxalate crystals differentiates it from ethylene glycol. *Methanol* - Methanol poisoning causes a **high anion gap metabolic acidosis**, visual disturbances (e.g., "snowstorm" vision), and central nervous system depression. - It does not typically lead to **hypocalcemia** or the kidney damage associated with calcium oxalate crystal formation. *Isopropanol* - Isopropanol (rubbing alcohol) poisoning causes **CNS depression**, **hypotension**, and an **osmolar gap** without significant anion gap metabolic acidosis. - It does not cause **hypocalcemia** or the high anion gap metabolic acidosis characteristic of ethylene glycol toxicity. *Digoxin* - Digoxin toxicity primarily affects the **cardiac system**, causing bradycardia, arrhythmias (e.g., ventricular fibrillation, heart block), and **gastrointestinal symptoms**. - It does not cause a high anion gap metabolic acidosis, hypocalcemia, or the other systemic sympathetic effects described in the scenario.

Q: A 45-year-old male with a history of chronic alcohol use is admitted to the hospital. He presents with anxiety, tremors, and agitation after his last drink 24 hours ago. Which of the following medications is most appropriate for controlling alcohol withdrawal symptoms?

Lorazepam. ***Lorazepam*** - **Lorazepam**, a **benzodiazepine**, is the first-line treatment for alcohol withdrawal symptoms due to its ability to enhance **GABAergic activity**, which is deficient during withdrawal. - Its **intermediate half-life** and **lack of active metabolites** make it suitable for patients with liver impairment, common in chronic alcohol users. *Fomepizole* - **Fomepizole** is an antidote used to treat poisoning from **methanol** or **ethylene glycol**, not alcohol withdrawal. - It works by inhibiting **alcohol dehydrogenase**, an enzyme involved in the metabolism of these toxic alcohols. *Disulfiram* - **Disulfiram** is an **aldehyde dehydrogenase inhibitor** used to deter alcohol consumption in recovering alcoholics by causing unpleasant reactions if alcohol is consumed. - It is **not used to treat acute alcohol withdrawal symptoms** and can be dangerous if given during withdrawal due to potential interactions. *Buspirone* - **Buspirone** is an **anxiolytic** that acts as a **serotonin receptor agonist** and is used for generalized anxiety disorder. - It is **ineffective for acute alcohol withdrawal** due to its slow onset of action and lack of anticonvulsant properties. *Naltrexone* - **Naltrexone** is an **opioid receptor antagonist** used for relapse prevention and reducing alcohol craving in patients with alcohol use disorder. - It is **not effective for acute alcohol withdrawal symptoms** and does not prevent seizures or delirium tremens, which are life-threatening complications of withdrawal.

Q: A patient being treated for hypertriglyceridemia developed flushing, gout, hyperglycemia, and raised liver enzymes. Which drug is the most likely cause?

Nicotinic acid. ***Nicotinic acid*** - **Nicotinic acid (Niacin)** is known to cause **flushing** due to prostaglandin release. - It also commonly leads to **hyperglycemia**, **hyperuricemia** (which can precipitate gout), and **elevated liver enzymes** as side effects. *Atorvastatin* - While atorvastatin can cause **elevated liver enzymes** and, less commonly, **myopathy**, it does not typically cause flushing, gout, or hyperglycemia. - Its primary role is to lower **LDL cholesterol**, with a lesser effect on triglycerides. *Fenofibrate* - **Fenofibrate** is used to treat hypertriglyceridemia and can rarely cause **elevated liver enzymes** and **gallstones**. - It is not associated with significant flushing, hyperglycemia, or gout. *Gemfibrozil* - **Gemfibrozil** is another fibrate used for hypertriglyceridemia treatment. - While it can cause **elevated liver enzymes** and **myopathy** (especially when combined with statins), it does not cause the characteristic flushing or hyperglycemia seen with nicotinic acid. *Ezetimibe* - **Ezetimibe** primarily inhibits cholesterol absorption and is generally well-tolerated. - Common side effects are mild and include abdominal pain and diarrhea, with no association to flushing, gout, or hyperglycemia.

Q: Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?

Volume of distribution. ***Volume of distribution*** - The **loading dose** of a drug is primarily determined by its **volume of distribution (Vd)** and the **target plasma concentration**. - A larger **Vd** means the drug distributes widely into tissues, requiring a larger loading dose to achieve the desired concentration in the central compartment. *Clearance* - **Clearance** dictates the **maintenance dose** needed to sustain a steady-state concentration once the loading dose has been administered. - It reflects the rate at which the drug is eliminated from the body, not how much is initially needed to fill the distribution volume. *Half-life* - **Half-life** determines the **time required to reach steady-state** and the **dosing interval** for maintaining therapeutic concentrations. - While related to clearance and Vd, it does not directly determine the magnitude of the initial loading dose itself. *Bioavailability* - **Bioavailability** is the fraction of administered drug that reaches the systemic circulation in an unchanged form. - It influences the oral dose required to achieve a certain plasma concentration, but the concept of loading dose is typically considered for the intravenous route where bioavailability is 100%. *Elimination rate constant* - The **elimination rate constant (ke)** describes the rate of drug elimination and is related to clearance and volume of distribution (ke = Cl/Vd). - Like clearance, it determines the **maintenance dose** and dosing frequency, not the initial loading dose required to achieve therapeutic levels.

Question 1

Which antithyroid drug is safer during the first trimester of pregnancy?

Accepted Answer

Propylthiouracil

Answer

Radioactive iodine

Answer

Carbimazole

Answer

Methimazole

Answer

Propranolol

Question 2

A patient on SSRI sertraline was also prescribed amitriptyline and subsequently developed serotonin toxicity. What is the likely treatment for serotonin toxicity?

Accepted Answer

Cyproheptadine

Answer

Flumazenil

Answer

L-Carnitine

Answer

Leucovorin

Answer

Naloxone

Question 3

Which of the following drugs is used in opioid maintenance therapy?

Accepted Answer

Buprenorphine

Answer

Naltrexone

Answer

Clonidine

Answer

Disulfiram

Answer

Naloxone

Question 4

Which of the following growth hormone analogues is not used for the treatment of GH deficiency but is used in the treatment of HIV associated lipodystrophy?

Accepted Answer

Tesamorelin

Answer

Sermorelin

Answer

Somatropin

Answer

Pegvisomant

Answer

Mecasermin

Question 5

Caffeine is a widely used stimulant that promotes wakefulness. Which of the following mechanisms is responsible for this effect?

Accepted Answer

Adenosine antagonism

Answer

Increased discharge of norepinephrine from the locus ceruleus

Answer

Release of histamine

Answer

Inhibition of phosphodiesterase

Answer

Dopamine reuptake inhibition

Question 6

Which of the following is commonly used for maintenance therapy in opioid abuse?

Accepted Answer

Buprenorphine

Answer

Clonidine

Answer

Butorphanol

Answer

Naloxone

Answer

Methadone

Question 7

A patient presents with symptoms of tachycardia, tachypnea, hypertension, and hypocalcemia after consuming an unknown substance. The patient also has high anion gap metabolic acidosis. Which of the following substances was most likely consumed?

Accepted Answer

Ethylene glycol

Answer

Iron

Answer

Methanol

Answer

Digoxin

Answer

Isopropanol

Question 8

A 45-year-old male with a history of chronic alcohol use is admitted to the hospital. He presents with anxiety, tremors, and agitation after his last drink 24 hours ago. Which of the following medications is most appropriate for controlling alcohol withdrawal symptoms?

Accepted Answer

Lorazepam

Answer

Fomepizole

Answer

Disulfiram

Answer

Buspirone

Answer

Naltrexone

Question 9

A patient being treated for hypertriglyceridemia developed flushing, gout, hyperglycemia, and raised liver enzymes. Which drug is the most likely cause?

Accepted Answer

Nicotinic acid

Answer

Atorvastatin

Answer

Fenofibrate

Answer

Ezetimibe

Answer

Gemfibrozil

Question 10

Lidocaine is used in a loading dose for the treatment of arrhythmias. The loading dose of this drug depends upon which of the following factors?

Accepted Answer

Volume of distribution

Answer

Clearance

Answer

Half-life

Answer

Bioavailability

Answer

Elimination rate constant

Autonomic/CV Drugs — MCQs

Autonomic/CV Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?